Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial
- 5 August 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 378 (9789), 412-419
- https://doi.org/10.1016/s0140-6736(11)60886-6
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Rituximab, B-Lymphocyte Depletion, and Preservation of Beta-Cell FunctionThe New England Journal of Medicine, 2009
- GAD Treatment and Insulin Secretion in Recent-Onset Type 1 DiabetesThe New England Journal of Medicine, 2008
- Type 1 diabetes as a relapsing–remitting disease?Nature Reviews Immunology, 2007
- A two-signal model for T cell traffickingTrends in Immunology, 2007
- CTLA4Ig: Bridging the Basic Immunology with Clinical ApplicationImmunity, 2006
- Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 DiabetesThe New England Journal of Medicine, 2005
- C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell FunctionDiabetes, 2004
- β-Cell Function and the Development of Diabetes-Related Complications in the Diabetes Control and Complications TrialDiabetes Care, 2003
- Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes MellitusThe New England Journal of Medicine, 2002
- Effect of Intensive Therapy on Residual β-Cell Function in Patients with Type 1 Diabetes in the Diabetes Control and Complications TrialAnnals of Internal Medicine, 1998